OBJECTIVE: The Th2-type CC chemokine thymus and activation-regulated chemokine (TARC/CCL17) is one of the high affinity ligands for CCR4, a chemokine receptor predominantly expressed by Th2 cells. We examined serum and plasma concentrations of TARC/CCL17 in patients with systemic lupus erythematosus (SLE). METHODS: Serum and plasma levels of TARC/CCL17 and plasma levels of monocyte chemoattractant protein-1 (MCP-1/CCL2) and macrophage-derived chemokine (MDC/CCL22) in patients with SLE were determined by ELISA. RESULTS: There were significant differences in the plasma concentrations of TARC/CCL17 between the patients with untreated SLE and treated SLE (p < 0.001), rheumatoid arthritis (RA) (p < 0.001), and healthy controls (p < 0.001). In addition, the plasma levels of TARC/CCL17 correlated with the class of lupus nephritis (higher in class I or II than in class III or IV). There was close correlation between plasma levels of MDC/CCL22 and TARC/CCL17. There was no correlation between plasma levels of MCP-1/CCL2 and TARC/CCL17. CONCLUSION: TARC/CCL17 may be a useful serological marker and may facilitate an assessment of the degree of disease activity in SLE. The development of SLE is closely related to the elevation of plasma TARC/CCL17 levels.
OBJECTIVE: The Th2-type CC chemokine thymus and activation-regulated chemokine (TARC/CCL17) is one of the high affinity ligands for CCR4, a chemokine receptor predominantly expressed by Th2 cells. We examined serum and plasma concentrations of TARC/CCL17 in patients with systemic lupus erythematosus (SLE). METHODS: Serum and plasma levels of TARC/CCL17 and plasma levels of monocyte chemoattractant protein-1 (MCP-1/CCL2) and macrophage-derived chemokine (MDC/CCL22) in patients with SLE were determined by ELISA. RESULTS: There were significant differences in the plasma concentrations of TARC/CCL17 between the patients with untreated SLE and treated SLE (p < 0.001), rheumatoid arthritis (RA) (p < 0.001), and healthy controls (p < 0.001). In addition, the plasma levels of TARC/CCL17 correlated with the class of lupus nephritis (higher in class I or II than in class III or IV). There was close correlation between plasma levels of MDC/CCL22 and TARC/CCL17. There was no correlation between plasma levels of MCP-1/CCL2 and TARC/CCL17. CONCLUSION:TARC/CCL17 may be a useful serological marker and may facilitate an assessment of the degree of disease activity in SLE. The development of SLE is closely related to the elevation of plasma TARC/CCL17 levels.
Authors: Andrew D Cook; Ming-Chin Lee; Reem Saleh; Hsu-Wei Khiew; Anne D Christensen; Adrian Achuthan; Andrew J Fleetwood; Derek C Lacey; Julia E Smith; Irmgard Förster; John A Hamilton Journal: JCI Insight Date: 2018-03-22
Authors: Adrian Achuthan; Andrew D Cook; Ming-Chin Lee; Reem Saleh; Hsu-Wei Khiew; Melody W N Chang; Cynthia Louis; Andrew J Fleetwood; Derek C Lacey; Anne D Christensen; Ashlee T Frye; Pui Yeng Lam; Hitoshi Kusano; Koji Nomura; Nancy Steiner; Irmgard Förster; Stephen L Nutt; Moshe Olshansky; Stephen J Turner; John A Hamilton Journal: J Clin Invest Date: 2016-08-15 Impact factor: 14.808
Authors: Shao Bo Su; Rafael S Grajewski; Dror Luger; Rajeev K Agarwal; Phyllis B Silver; Jun Tang; Jingsheng Tuo; Chi-Chao Chan; Rachel R Caspi Journal: Invest Ophthalmol Vis Sci Date: 2007-10 Impact factor: 4.799
Authors: Ming-Chin Lee; Reem Saleh; Adrian Achuthan; Andrew J Fleetwood; Irmgard Förster; John A Hamilton; Andrew D Cook Journal: Arthritis Res Ther Date: 2018-04-05 Impact factor: 5.156